Cooper Companies (The)

CEO Al White has deep company tenure spanning finance, strategy and operating roles, and the board appointed Colleen Jay as chair effective January 2, 2026. The team navigated FY25 with earnings growth, higher FCF and a strategic review responding to shareholder input.

Execution credibility is solid in vision care; surgical oversight needs continued strengthening given litigation and 2024 internal‑control remediation at CooperSurgical (since remediated in FY25). Overall, leadership is responsive and increasingly focused on value creation, though we remain watchful on surgical risk management.